The U.S. Food and Drug Administration is launching a program to reward companies with accelerated drug review and speedy agency feedback, if their actions align with the agency’s national health ...

The drug, Ibtrozi, will now vie for market share in an indication where multiple large pharmaceutical companies have already ...

Pfizer Inc. plans to spend billions of dollars to join the race for a new type of cancer treatment. Similar to its competitors, Pfizer also plans to partner with a Chinese company. The company PFE ...

Its dividend: The stock recently yielded a whopping 7.3%. That's hard to beat and will generate around $730 for every $10,000 ...

(Reuters) -An experimental treatment by Pfizer and Arvinas delayed progression of breast cancer by more than three months compared to AstraZeneca's Faslodex in patients with a specific gene ...

June 6 (UPI) --Longtime ESPN Sports Center anchor Jay Harris has been diagnosed with prostate cancer and is scheduled to have surgery Tuesday. Harris, 60, wrote about his experience in an essay ...

The application covers vepdegestrant for patients with ER-positive (ER+)/human epidermal growth factor receptor 2 (HER2)-negative (ER+/HER2-) ESR1-mutated advanced or metastatic breast cancer ...

Prostate cancer is one of the most common cancers found in U.S. men. If detected early, prostate cancer is often highly treatable before it spreads. But the American Cancer Society estimates there ...

Dr Petros Grivas surveys several exciting developments in prostate cancer research, including AI-driven biomarker analysis from the STAMPEDE trial, to identify high-risk patients who may benefit ...

LOS ANGELES — Jay Harris, an ESPN "SportsCenter" anchor, has announced he will be missing from the program for about a month after being diagnosed with prostate cancer. The announcement was made ...